Capponi Vincent

SEC source: 0001104659-26-108247 · tm2625479-1_4seq1.xml · nonDerivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,387

F1 · shares: This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and

F4 · balance_after: (continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person.

F5 · balance_after: Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.

SEC source: 0001104659-26-108247 · tm2625479-1_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,114

F1 · shares: This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 505 RSUs granted on March 15, 2018, (b) 895 RSUs granted on February 24, 2017, (c) 2,700 RSUs granted on June 7, 2016 and (d) 6,250 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 4,455 RSUs granted on August 8, 2025 and of which 2,228 remain unvested as of the date hereof; and

F4 · balance_after: (continued from footnote 3) (iii) 25,736 shares of Common Stock owned by the Reporting Person.

F5 · balance_after: Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.

SEC source: 0001104659-25-075792 · tm2522995-4_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,100

Underlying: Common Stock · 111,100 shares

Expires 2035-08-08

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-25-075792 · tm2522995-4_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 766,268

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 81,000 RSUs granted on April 2, 2024 and of which 40,500 remain unvested as of the date hereof; and

F4 · balance_after: (continued from footnote 3) (iii) 429,668 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-25-017621 · tm257709-4_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires 2025-02-24

F1 · security: On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the Reporting Person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F2 · derivative.exercise_price: The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F6 · balance_after: The Reporting Person's remaining 19,760 Series A Warrants expired unexercised on February 24, 2025.

SEC source: 0001104659-25-017621 · tm257709-4_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 677,168

F1 · security: On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the Reporting Person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F2 · price: The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F3 · balance_after: Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date) and will settle into shares of common stock, par value $0.001 per share (the "Common Stock"), of the Company upon vesting: 73,000 RSUs granted on July 7, 2023 and of which 24,334 RSUs remain unvested as of the date hereof;

F4 · balance_after: (continued from footnote 3) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F5 · balance_after: (continued from footnote 4) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 81,000 RSUs granted on April 2, 2024 and remain unvested as of the date hereof; and 5. (continued from footnote 4) (iv) 364,834 shares of Common Stock owned by the Reporting Person.

SEC source: 0001104659-25-005356 · tm254168-3_4seq1.xml · derivative · entry 4

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,760

Underlying: Common Stock · 31,760 shares

Expires 2025-04-10

F1 · security: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F8 · derivative.exercise_price: The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.

F8 · price: The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.

F9 · derivative.expiration_date: The Series B Right Warrants expire 90 calendar days following the Closing Date.

SEC source: 0001104659-25-005356 · tm254168-3_4seq1.xml · derivative · entry 3

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,760

Underlying: Common Stock · 31,760 shares

Expires 2025-02-24

F1 · security: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F6 · derivative.exercise_price: The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F6 · price: The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.

F7 · derivative.expiration_date: The Series A Right Warrants expire 45 calendar days following the Closing Date.

SEC source: 0001104659-25-005356 · tm254168-3_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 31,760 shares

Expires 2025-01-10

F1 · kind: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the "Closing Date").

SEC source: 0001104659-25-005356 · tm254168-3_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 665,168

F1 · kind: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F1 · price: On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the "Closing Date").

F2 · balance_after: Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of common stock, par value $0.001 per share (the "Common Stock"), of the Company upon vesting: 73,000 RSUs granted on July 7, 2023 and of which 24,334 RSUs remain unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 81,000 RSUs granted on April 2, 2024 and remain unvested as of the date hereof; and

F5 · balance_after: (continued from footnote 4) (iv) 352,834 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-24-107141 · tm2425809-1_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-10-04

F2 · price: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR before, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

F2 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR before, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-107141 · tm2425809-1_4seq1.xml · derivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-10-04

F1 · price: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043790 · tm2411149-4_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,000

Underlying: Common Stock · 101,000 shares

Expires 2034-04-02

F6 · price: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-24-043790 · tm2411149-4_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 665,134

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of common stock, par value $0.001 per share (the "Common Stock"), of the Company upon vesting: 73,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 23,000 RSUs granted on August 10, 2022 and unvested as of the date hereof; and

F5 · balance_after: (continued from footnote 4) (iv) 281,134 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-24-042775 · tm2410664-3_4seq1.xml · derivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,923

Underlying: Common Stock · 129,998 shares

Expires 2034-03-29

F1 · price: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

F1 · derivative.exercise_date: The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-126430 · tm2332958-6_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,578

Underlying: Common Stock · 6,578 shares

Expires 2028-12-13

F1 · kind: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

SEC source: 0001104659-23-126430 · tm2332958-6_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 584,134

F1 · shares: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F1 · price: These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.

F2 · balance_after: Includes (i) the following restricted stock units ("RSUs") (which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: 73,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;

F3 · balance_after: (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F4 · balance_after: (continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 23,000 RSUs granted on August 10, 2022 and unvested as of the date hereof; and

F5 · balance_after: (continued from footnote 4) (iv) 281,134 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-080100 · tm2321021-2_4seq1.xml · derivative · entry 3

Capponi Vincent · CIK 0001368151 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Common Stock · 42,000 shares

Expires 2033-07-07

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on each of the first anniversary of the date of grant and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080100 · tm2321021-2_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,000

Underlying: Common Stock · 91,000 shares

Expires 2033-07-07

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first anniversary of the date of grant, one-fourth of the award on the second anniversary of the date of grant, and one-fourth of the award on the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-23-080100 · tm2321021-2_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 576,153

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to two-thirds of the award on the first anniversary of the date of grant and shall vest as to one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes (a) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 10,100 RSUs granted on March 15, 2018, (ii) 17,900 RSUs granted on February 24, 2017, (iii) 54,000 RSUs granted on June 7, 2016 and (iv) 125,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs: (i) 46,000 RSUs granted on August 10, 2022 and unvested as of the date hereof (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and (ii) 73,000 RSUs granted on July 7, 2023 and reported on this Form 4; and

F4 · balance_after: (continued from footnote 3) (c) 250,153 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-23-042297 · tm2311913d1_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2023-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: These stock options were originally granted on April 4, 2013 and became exercisable at the discretion of the Board of Directors of the Company upon the achievement of certain milestones connected to the Company's operations.

SEC source: 0001104659-23-042297 · tm2311913d1_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 511,989

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes (a) the following restricted stock units ("RSUs") that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F2 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 46,000 RSUS granted on August 10, 2021 and unvested on the date hereof ; and

F3 · balance_after: (continued from footnote 3) (c) 238,250 shares of Common Stock owned by the reporting person, inclusive of the 10,000 shares reported on this Form 4.

SEC source: 0001104659-22-090252 · tm2223355-4_4seq1.xml · derivative · entry 3

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2032-08-10

F6 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest only upon the achievement of certain milestones before December 31, 2025. Specifically, (i) 70,000 options will vest if the Company obtains U.S. Food and Drug Administration approval for its product DrugSorb, (ii) 50,000 options will vest if the Company achieves $80 million or more in annual ex-U.S. sales, (iii) 100,000 options will vest if the Company achieves $20 million or more in annual U.S. sales, and (iv) 30,000 options will vest if the Company achieves U.S. GAAP breakeven.

SEC source: 0001104659-22-090252 · tm2223355-4_4seq1.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,000

Underlying: Common Stock · 86,000 shares

Expires 2032-08-10

F5 · derivative.exercise_date: These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-22-090252 · tm2223355-4_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 512,545

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting.

F2 · balance_after: Includes (a) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 10,100 RSUs granted on March 15, 2018, (ii) 17,900 RSUs granted on February 24, 2017, (iii) 54,000 RSUs granted on June 7, 2016 and (iv) 125,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (i) 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof and (ii) 69,000 RSUs granted on August 10, 2022 reported on this Form 4 and unvested on the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 215,806 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-22-073622 · tm2219169-1_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 443,545

F1 · kind: The transactions reported on this Form 4 were open market purchases made by the reporting person pursuant to a 10b5-1 trading plan adopted by the reporting person that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes (a) the following restricted stock units ("RSUs") that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 10,100 RSUs granted on March 15, 2018, (ii) 17,900 RSUs granted on February 24, 2017, (iii) 54,000 RSUs granted on June 7, 2016 and (iv) 125,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 215,806 shares of Common Stock owned by the reporting person, inclusive of the 2,000 shares purchased on June 21, 2022 and reported on this Form 4.

SEC source: 0001104659-22-072985 · tm2218917-2_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 441,545

F1 · kind: The transactions reported on this Form 4 were open market purchases made by the reporting person pursuant to a 10b5-1 trading plan adopted by the reporting person that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes (a) the following restricted stock units ("RSUs") that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F3 · balance_after: (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof; and

F4 · balance_after: (continued from footnote 3) (c) 213,806 shares of Common Stock owned by the reporting person, inclusive of the 3,000 shares purchased on June 16, 2022 and reported on this Form 4.

SEC source: 0001104659-22-064664 · tm2216877-1_4seq1.xml · nonDerivative · entry 3

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 438,545

F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F2 · balance_after: (continued from footnote 1) (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof; and

F3 · balance_after: (continued from footnote 2) (iii) 210,806 shares of Common Stock owned by the reporting person, inclusive of the shares purchased on May 23, 2022 and reported on this Form 4.

SEC source: 0001104659-22-064664 · tm2216877-1_4seq1.xml · nonDerivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,418

SEC source: 0001104659-22-064664 · tm2216877-1_4seq1.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,119

SEC source: 0001104659-21-050397 · tm2113016d3_4.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,200

Underlying: Common Stock · 78,200 shares

Expires 2031-04-12

F4 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-21-050397 · tm2113016d3_4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 467,756

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

F3 · balance_after: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 62,215 RSUs granted on April 12, 2021 and unvested on the date hereof; (b) 18,034 RSUs granted on February 28, 2020 and unvested on the date hereof; and (c) 18,034 RSUs granted on July 22, 2019 and unvested on the date hereof; and (iii) 162,473 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-20-058219 · tm2019006d2_4.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,123 shares

Expires 2020-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: These stock options were originally granted on May 5, 2010 and became exercisable at the discretion of the Board of Directors of the Company based on criteria including (but not limited to) a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development.

SEC source: 0001104659-20-058219 · tm2019006d2_4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 427,772

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes: (i) the following RSUs that will be settled into common stock, par value $0.0001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018; (continue with footnote 2)

F2 · balance_after: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 36,067 RSUs granted on February 28, 2020 and unvested on the date hereof; (b) 36,067 RSUs granted on July 22, 2019 and unvested on the date hereof; and (c) 1,540 RSUs granted on March 4, 2019 and unvested on the date hereof; and (iii) 147,098 shares of Common Stock owned by the reporting person.

SEC source: 0001104659-20-053381 · tm2018085-1_4.xml · derivative · entry 3

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 10,000 shares

Expires 2023-04-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Stock option exercise conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F6 · derivative.exercise_date: These stock options were originally granted on April 4, 2013 and became exercisable based on the achievement of certain milestones connected to the Company's operations, subject to approval by the Board of Directors.

SEC source: 0001104659-20-053381 · tm2018085-1_4.xml · nonDerivative · entry 2

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 417,649

F2 · kind: Open market sale conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Exchange Act.

F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.01

F4 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018;

F5 · balance_after: (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into common stock, par value $0.001 per share (the "Common Stock") of the Company upon vesting: (a) 36,067 RSUs granted on February 28, 2020 and unvested on the date hereof; (b) 36,067 RSUs granted on July 22, 2019 and unvested on the date hereof; and (c) 1,540 RSUs granted on March 4, 2019 and unvested on the date hereof; and (iii) 136,975 shares of common stock owned by the reporting person.

SEC source: 0001104659-20-053381 · tm2018085-1_4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 427,649

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Stock option exercise conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

SEC source: 0001104659-20-032715 · tm2011575d4_form4.xml · derivative · entry 5

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,123

Underlying: Common Stock · 4,677 shares

Expires 2020-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Stock option exercise conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F5 · derivative.exercise_date: These stock options were originally granted on May 5, 2010 and vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development.

SEC source: 0001104659-20-032715 · tm2011575d4_form4.xml · derivative · entry 4

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,800

Underlying: Common Stock · 6,500 shares

Expires 2020-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Stock option exercise conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F5 · derivative.exercise_date: These stock options were originally granted on May 5, 2010 and vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development.

SEC source: 0001104659-20-032715 · tm2011575d4_form4.xml · nonDerivative · entry 3

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 417,649

F2 · kind: Open market sale conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Exchange Act.

F3 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018; and (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into common stock, par value $0.001 per share (the "Common Stock") of the Company upon vesting: (a) 36,067 RSUs granted on February 28, 2020 and unvested on the date hereof; (b) 36,067 RSUs granted on July 22, 2019 and unvested on the date hereof; (continued in footnote 4)

F4 · balance_after: (continued from footnote 3) and (c) 1,540 RSUs granted on March 4, 2019 and unvested on the date hereof; and (iii) 136,975 shares of common stock owned by the reporting person.

SEC source: 0001104659-20-032715 · tm2011575d4_form4.xml · nonDerivative · entry 2

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 422,326

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Stock option exercise conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

SEC source: 0001104659-20-032715 · tm2011575d4_form4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 417,649

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Stock option exercise conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

SEC source: 0001104659-20-028657 · tm2011575d4_form4.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,000

Underlying: Common Stock · 68,000 shares

Expires 2030-02-28

F3 · derivative.exercise_date: The stock options were granted pursuant to the Plan. The shares underlying the stock options vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001104659-20-028657 · tm2011575d4_form4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 420,849

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018; and (ii) the following RSUs subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting: (a) 54,100 RSUs granted on February 28, 2020 as reported on this Form 4; (b) 36,067 RSUs granted on July 22, 2019 and unvested on the date hereof; and (c) 3,080 RSUs granted on March 4, 2019 and unvested on the date hereof; and (iii) 120,602 shares of common stock owned by the reporting person.

SEC source: 0001144204-19-040420 · tv527862_4.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,400

Underlying: Common Stock · 4,600 shares

Expires 2020-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, representing a right to purchase a total of 20,000 shares of common stock (after giving effect to the issuer's twenty-five-for-one reverse split) became exercisable in five equal annual installments, with the first installment vesting on the date of grant.

SEC source: 0001144204-19-040420 · tv527862_4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 372,501

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of the issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015; (ii) the following RSUs subject to vesting in three equal annual installments with the first of such vesting beginning on the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 36,067 RSUs granted on July 22, 2019 and unvested as of the date hereof,

F2 · balance_after: (b) 3,080 granted on March 4, 2019 and unvested as of the date hereof and (c) 12,667 RSUs granted on February 28, 2018 and unvested as of the date hereof; and (iii) 113,687 shares of common stock owned by the reporting person, inclusive of the 4,600 shares of common stock reported on this Form 4.

SEC source: 0001144204-19-035842 · tv525808_4.xml · derivative · entry 2

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,000

Underlying: Common Stock · 68,000 shares

Expires 2029-07-22

F3 · derivative.exercise_date: The stock option was granted pursuant to the Plan. The shares underlying the stock option vest as to one-quarter of the award on each of the date of grant, the first anniversary of the date of grant, the second anniversary of the date of grant and the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC source: 0001144204-19-035842 · tv525808_4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,322

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018; (ii) the following RSUs subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting: (a) 54,100 RSUs granted on July 22, 2019 and reported on this Form 4, (b) 12,667 RSUs granted on February 28, 2018 and unvested as of the date hereof and (c) 3,080 RSUs granted on March 4, 2019 and unvested as of the date hereof; and (iii) 99,475 shares of common stock owned by the reporting person.

SEC source: 0001144204-19-012637 · tv515704_4.xml · nonDerivative · entry 1

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,435

F1 · shares: These shares represent restricted stock units ("RSUs") which shall vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 12,667 RSUs granted on February 28, 2018 and unvested as of the date hereof and (b) 4,620 granted on March 4, 2019 and reported on this Form 4 and (iii) 101,148 shares of common stock owned by the reporting person.

SEC source: 0001144204-18-047558 · tv502184_4.xml · derivative · entry 3

Capponi Vincent · CIK 0001368151 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,300

Underlying: Common Stock · 20,000 shares

Expires 2020-05-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · derivative.exercise_date: These stock options vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development. The options did not vest on May 5, 2010.